Literature DB >> 17256726

A genomewide DNA microsatellite association study of Japanese patients with autoimmune hepatitis type 1.

Shuichi Yokosawa1, Kaname Yoshizawa, Masao Ota, Yoshihiko Katsuyama, Shigeyuki Kawa, Tetsuya Ichijo, Takeji Umemura, Eiji Tanaka, Kendo Kiyosawa.   

Abstract

UNLABELLED: Genetic predisposition to type 1 autoimmune hepatitis (AIH) is linked mainly to HLA class II genes. We previously searched the whole HLA region for AIH susceptibility genes using microsatellite markers and found only HLA-DR/DQ to be a candidate region for this suspected multifactorial disease. As such, the aim of this study was to broaden our search and screen the whole genome for additional genes that might contribute to type 1 AIH susceptibility. Eighty-one patients with type 1 AIH (15 men, 66 women, average age 55.9) and 80 healthy sex- and age-matched Japanese controls were enrolled in this study. We performed a case-control association study using 400 polymorphic microsatellite markers with an average spacing of 10.8 cM distributed throughout the whole genome. Two markers, one on chromosome 11 (D11S902, Pc = 0.013) and one on chromosome 18 (D18S464, Pc = 0.008), were revealed to have statistically significant associations with AIH. An additional 7 markers (D2S367, D6S309, D9S273, D11S1320, D16S423, D17S938, and D18S68) were also found to be candidate susceptibility regions. In addition, our results showed there were 17 regions that may contain genes of resistance to AIH. No specific markers were detected in HLA-DR4-negative patients, and no differences were seen in the clinical courses of patients (severe versus mild to moderate).
CONCLUSION: This first genomewide scan of Japanese AIH patients revealed at least 26 candidate AIH susceptibility or resistance regions other than HLA class II loci. These results also suggested that the products of several genes interact to determine heritable susceptibility to AIH.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17256726     DOI: 10.1002/hep.21518

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  14 in total

Review 1.  Emerging opportunities for site-specific molecular and cellular interventions in autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2010-01-27       Impact factor: 3.199

2.  Childhood autoimmune hepatitis in a paediatric unit of a tertiary care hospital.

Authors:  Ai Sha Low; Michelle Tan; Agatha Garcia; Marion Aw; Seng Hock Quak
Journal:  Singapore Med J       Date:  2014-12       Impact factor: 1.858

Review 3.  Transitioning from Idiopathic to Explainable Autoimmune Hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2015-05-22       Impact factor: 3.199

Review 4.  Autoimmune Hepatitis: Surviving Crises of Doubt and Elimination.

Authors:  Albert J Czaja
Journal:  Clin Liver Dis (Hoboken)       Date:  2020-03-02

5.  Autoimmune hepatitis: 50 Years of (slow) progress.

Authors:  M Eric Gershwin; Edward L Krawitt
Journal:  Hepatology       Date:  2014-03       Impact factor: 17.425

Review 6.  Under-Evaluated or Unassessed Pathogenic Pathways in Autoimmune Hepatitis and Implications for Future Management.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2018-04-18       Impact factor: 3.199

Review 7.  Acute and acute severe (fulminant) autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2012-10-23       Impact factor: 3.199

Review 8.  Aetiopathogenesis of autoimmune hepatitis.

Authors:  Diego Vergani; Giorgina Mieli-Vergani
Journal:  World J Gastroenterol       Date:  2008-06-07       Impact factor: 5.742

Review 9.  Update on autoimmune hepatitis.

Authors:  Andreas Teufel; Peter R Galle; Stephan Kanzler
Journal:  World J Gastroenterol       Date:  2009-03-07       Impact factor: 5.742

Review 10.  Genetic factors affect the etiology, clinical characteristics and outcome of autoimmune hepatitis.

Authors:  Takeji Umemura; Masao Ota
Journal:  Clin J Gastroenterol       Date:  2015-12-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.